Compass Pathways PLC Sponsored ADR (NASDAQ:CMPS) Receives Consensus Rating of “Moderate Buy” from Analysts

Shares of Compass Pathways PLC Sponsored ADR (NASDAQ:CMPS) have earned an average recommendation of “Moderate Buy” from the fourteen analysts that are currently covering the stock, Marketbeat.com reports. One research analyst has rated the stock with a sell recommendation, one has issued a hold recommendation, ten have issued a buy recommendation and two have given a strong buy recommendation to the company. The average 1 year price target among analysts that have issued ratings on the stock in the last year is $21.3636.

CMPS has been the subject of several recent research reports. Wolfe Research initiated coverage on Compass Pathways in a research note on Friday, May 22nd. They issued an “outperform” rating for the company. TD Cowen restated a “buy” rating on shares of Compass Pathways in a report on Monday. B. Riley Financial assumed coverage on Compass Pathways in a report on Friday, April 24th. They issued a “buy” rating and a $17.00 target price for the company. Canaccord Genuity Group dropped their target price on Compass Pathways from $20.00 to $18.00 and set a “buy” rating for the company in a report on Thursday, March 26th. Finally, BTIG Research restated a “buy” rating and issued a $14.00 target price on shares of Compass Pathways in a report on Wednesday, May 13th.

Compass Pathways Stock Down 6.1%

NASDAQ CMPS opened at $13.33 on Friday. The business has a fifty day moving average price of $8.40 and a 200 day moving average price of $7.19. Compass Pathways has a one year low of $2.25 and a one year high of $14.76. The company has a debt-to-equity ratio of 0.15, a quick ratio of 3.32 and a current ratio of 3.32. The company has a market cap of $1.80 billion, a P/E ratio of -4.23 and a beta of 2.50.

Compass Pathways (NASDAQ:CMPS) last posted its quarterly earnings data on Wednesday, May 13th. The company reported ($0.30) EPS for the quarter, beating the consensus estimate of ($0.45) by $0.15. Research analysts anticipate that Compass Pathways will post -1.24 EPS for the current fiscal year.

Institutional Trading of Compass Pathways

Several large investors have recently added to or reduced their stakes in CMPS. EverSource Wealth Advisors LLC grew its holdings in Compass Pathways by 67.7% in the 1st quarter. EverSource Wealth Advisors LLC now owns 4,754 shares of the company’s stock valued at $26,000 after buying an additional 1,920 shares in the last quarter. Persistent Asset Partners Ltd purchased a new stake in Compass Pathways in the 4th quarter valued at $38,000. Parallel Advisors LLC grew its holdings in Compass Pathways by 8,450.6% in the 1st quarter. Parallel Advisors LLC now owns 7,268 shares of the company’s stock valued at $40,000 after buying an additional 7,183 shares in the last quarter. Advisory Services Network LLC purchased a new stake in Compass Pathways in the 3rd quarter valued at $41,000. Finally, North Star Investment Management Corp. grew its holdings in Compass Pathways by 1,354.0% in the 1st quarter. North Star Investment Management Corp. now owns 7,517 shares of the company’s stock valued at $42,000 after buying an additional 7,000 shares in the last quarter. 46.19% of the stock is currently owned by hedge funds and other institutional investors.

Compass Pathways Company Profile

Compass Pathways (NASDAQ: CMPS) is a clinical-stage biotechnology company focused on the development and commercialization of psilocybin therapy for mental health disorders. Founded in 2016 and headquartered in London with additional offices in the United States, Compass Pathways is pioneering the use of synthetic psilocybin combined with psychotherapy to address treatment-resistant depression. The company’s flagship program is a Phase IIb clinical trial evaluating COMP360, its proprietary psilocybin formulation, which has received Breakthrough Therapy designation from the U.S.